You are receiving this email because you are subscribed to Daily Insider Trades. If you no longer wish to receive these emails, please unsubscribe here. |
|
|
Targeting companies with recently announced takeover deals can often lead to low-risk gains.
The potential for profit is even higher if you buy shares of stocks that are receiving takeover interest or are actively exploring a sale. Share prices usually rise after a takeover deal has been announced, and takeover deals are frequently announced at a significant premium above current share prices.
Here are three takeover targets for the week - |
Theratechnologies Inc. – SYM: THTX
Recent Price: $2.54
Takeover Action: Future Pak announced that it has submitted two formal proposals since January to acquire all outstanding common shares of Theratechnologies. The most recent offer, which remains under consideration by Theratechnologies and its Board, proposes a cash consideration of $3.51 to $4.50 per share.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
|
PodcastOne, Inc. – SYM: PODC
Recent Price: $1.92
Takeover Action: Galloway Capital Partners, which holds a 2.28% stake in PodcastOne, urged the company's management to engage an investment bank or strategic advisor to explore options for enhancing shareholder value, including a possible sale, merger, or acquisition.
PodcastOne, Inc. operates as a podcast platform and publisher. The company offers its content to audiences through podcasting distribution platforms, including its website, Apple Podcasts, Spotify, Amazon Music, and others. It also produces vodcasts, branded podcasts, merchandise, and live events. In addition, the company builds, owns, and operates LaunchPadOne, a self-publishing podcast platform for independent podcasters. The company was formerly known as Courtside Group, Inc. and changed its name to PodcastOne, Inc. in September 2023. PodcastOne, Inc. is headquartered in Beverly Hills, California. PodcastOne, Inc. is a subsidiary of LiveOne, Inc. Click here to continue reading the full article and see our last pick. |
|
|
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Goldshore Resources (OTC: GSHRF). The compensation consists of up to $2,000 and was received/will be received from Investing Media Solutions. This compensation should not be considered as an endorsement of the securities of adviser Goldshore Resources (OTC: GSHRF) and we are not responsible for any errors or omissions in any information provided about the securities of Goldshore Resources (OTC: GSHRF) by Edge on the Street or Investing Media Solutions. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 4/22/2025. Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2025 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
|
|
|
Post a Comment
Post a Comment